Nurix Therapeutics, Inc. (NRIX)
NASDAQ·Healthcare·Biotechnology
$17.21
+4.34%
Mkt Cap $1.44B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q2 2026 Apr 8, 2026 | $14.25M | $6.25M | -56.13% | -$0.76 | -$0.79 | -3.95% | — | — |
| Q1 2026 Jan 28, 2026 | $13.40M | $13.58M | +1.33% | -$0.84 | -$0.82 | +2.38% | — | — |
| Q4 2025 Oct 9, 2025 | $12.26M | $7.89M | -35.61% | -$0.84 | -$1.03 | -22.62% | — | — |
| Q3 2025 Jul 9, 2025 | $17.51M | $44.06M | +151.56% | -$0.71 | -$0.52 | +26.76% | — | — |
| Q2 2025 Apr 8, 2025 | $15.82M | $18.45M | +16.61% | -$0.72 | -$0.67 | +6.94% | — | — |
| Q1 2025 Jan 28, 2025 | $14.78M | $13.28M | -10.11% | -$0.67 | -$0.75 | -11.94% | — | — |
| Q4 2024 Oct 11, 2024 | $12.81M | $12.59M | -1.73% | -$0.67 | -$0.67 | +0.00% | — | — |
| Q3 2024 Jul 11, 2024 | $22.10M | $12.09M | -45.29% | -$0.66 | -$0.71 | -7.58% | — | — |
| Q2 2024 Apr 10, 2024 | $17.30M | $16.59M | -4.13% | -$0.80 | -$0.76 | +5.00% | — | — |
| Q1 2024 Feb 15, 2024 | $22.26M | $15.16M | -31.90% | -$0.51 | -$0.77 | -50.98% | — | — |
| Q4 2023 Oct 12, 2023 | $15.98M | $18.47M | +15.56% | -$0.69 | -$0.68 | +1.45% | — | — |
| Q3 2023 Jul 13, 2023 | $26.21M | $30.68M | +17.04% | -$0.63 | -$0.45 | +28.57% | — | — |
| Q2 2023 Apr 13, 2023 | $10.87M | $12.69M | +16.70% | -$0.90 | -$0.75 | +16.67% | — | — |
| Q1 2023 Feb 9, 2023 | $17.17M | $6.78M | -60.50% | -$0.68 | -$0.87 | -27.94% | — | — |
| Q4 2022 Oct 6, 2022 | $12.07M | $10.79M | -10.61% | -$0.99 | -$0.90 | +9.09% | — | — |
| Q3 2022 Jul 7, 2022 | $10.51M | $11.43M | +8.82% | -$1.00 | -$1.01 | -1.00% | — | — |
| Q2 2022 Apr 7, 2022 | $9.27M | $9.62M | +3.75% | -$0.89 | -$0.95 | -6.74% | — | — |
| Q1 2022 Jan 27, 2022 | $13.19M | $7.40M | -43.95% | -$0.67 | -$0.85 | -26.87% | — | — |
| Q4 2021 Oct 14, 2021 | $10.41M | $10.25M | -1.49% | -$0.63 | -$0.65 | -3.17% | — | — |
| Q3 2021 Jul 13, 2021 | $8.23M | $7.09M | -13.84% | -$0.54 | -$0.60 | -11.11% | — | — |